Clostridioides difficile S-Layer Protein A (SlpA) Serves as a General Phage Receptor-Reference-Cited by-同舟云学术

Clostridioides difficile S-Layer Protein A (SlpA) Serves as a General Phage Receptor

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Royer Alexia L. M.¹²,Umansky Andrew A.¹,Allen Marie-Maude¹,Garneau Julian R.¹,Ospina-Bedoya Maicol¹,Kirk Joseph A.³,Govoni Gregory⁴,Fagan Robert P.³,Soutourina Olga²^ORCID,Fortier Louis-Charles¹^ORCID

Affiliation:

1. Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada

2. Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France

3. Molecular Microbiology, School of Biosciences, University of Sheffield, Sheffield, United Kingdom

4. AvidBiotics, South San Francisco, California, USA

Abstract

Phage therapy represents an interesting alternative to treat Clostridioides difficile infections because, contrary to antibiotics, most phages are highly species specific, thereby sparing the beneficial gut microbes that protect from infection. However, currently available phages against C. difficile have a narrow host range and target members from only one or a few PCR ribotypes.

Funder

Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.03894-22

Reference54 articles.

1. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance

2. Clostridioides difficile: diagnosis and treatments

3. Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo